Krystal Biotech Inc Dossier
Qualitative Analysis
Business overview
Krystal Biotech, Inc. (NASDAQ: KRYS) is a pioneering, commercial-stage biotechnology company specializing in the discovery, development, and commercialization of redosable gene therapies. The company's proprietary HSV-1-based gene therapy platform is designed to deliver therapeutic transgenes directly to target cells, bypassing the limitations of traditional viral vectors. Krystal's flagship product, VYJUVEK (beremagene geperpavec-svdt), is the first and only FDA-approved redosable gene therapy for the treatment of dystrophic epidermolysis bullosa (DEB), a rare and debilitating genetic skin disorder. The company operates as a single segment focused on genetic medicines, leveraging its in-house manufacturing capabilities to scale production and maintain high gross margins.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Expanding the commercial footprint of VYJUVEK globally beyond the United States, focusing on direct launches in major European markets (Germany, France, Italy) and Japan, while expanding the specialty distributor network to cover over 40 countries.
Expected impact: Establishes ex-U.S. markets as the predominant driver of top-line revenue growth and broadens the global patient base.
Leveraging the proprietary redosable HSV-1 vector platform (STAR-D) to advance multiple clinical candidates in dermatology, ophthalmology, and respiratory diseases, aiming to transition from a single-product company to a multi-product rare disease leader.
Expected impact: Reduces single-product dependency and targets treating over 10,000 patients globally by the end of the decade.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
High
Terms: Not publicly disclosed in detail; structured as a service and distribution agreement to support cold-chain logistics and home administration of VYJUVEK by specialized nurses.